Cyclic peptide compositions for treatment of sexual dysfunction
    41.
    发明授权
    Cyclic peptide compositions for treatment of sexual dysfunction 有权
    用于治疗性功能障碍的循环肽组合物

    公开(公告)号:US07473760B2

    公开(公告)日:2009-01-06

    申请号:US11269271

    申请日:2005-11-09

    IPC分类号: A61K38/00 A61K38/12 C07K7/00

    摘要: A cyclic peptide of the structural formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6, m, n and p are as defined. Further provided are compositions for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminus —OH group. Routes of administration include injection, oral, urethral, vaginal, nasal and mucosal administration.

    摘要翻译: 结构式的环状肽或其药学上可接受的盐,其中R 1,R 2,R 3,R 5,R 6,m,n和p如上所定义。 还提供了通过施用包括C末端-OH基团的环肽来治疗哺乳动物的性功能障碍的组合物,包括男性性功能障碍,例如勃起功能障碍和女性性功能障碍。 给药途径包括注射,口服,尿道,阴道,鼻和粘膜给药。

    Melanocortin receptor-specific piperazine compounds with diamine groups
    44.
    发明授权
    Melanocortin receptor-specific piperazine compounds with diamine groups 有权
    具有二胺基团的黑皮质素受体特异性哌嗪化合物

    公开(公告)号:US07968548B2

    公开(公告)日:2011-06-28

    申请号:US11464053

    申请日:2006-08-11

    IPC分类号: A61K31/495 C07D241/04

    摘要: Melanocortin receptor-specific compounds with diamine groups of the general formula and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.

    摘要翻译: 具有通式的二胺基的黑皮质素受体特异性化合物及其药学上可接受的盐,其中W是具有至少一个阳离子中心,氢键供体或氢键受体的二胺杂原子单元,J,Q,L1,L2,L3, R1a,R1b,R2a,R2b和X如本说明书中所定义,并且带有星号的碳原子可具有任何立体化学构型。 本文公开的化合物结合一种或多种黑皮质素受体,并且可以是关于一种或多种黑皮质素受体的反向激动剂的激动剂,部分激动剂,拮抗剂,反向激动剂或拮抗剂,并且可以用于治疗一种或多种黑皮质素受体 更多的黑皮质素受体相关病症或障碍,包括特别治疗肥胖症和相关病症。

    Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
    45.
    发明授权
    Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds 失效
    噻吩并[2,3-D]嘧啶-2,4-二酮黑皮质素特异性化合物

    公开(公告)号:US07655658B2

    公开(公告)日:2010-02-02

    申请号:US11040838

    申请日:2005-01-21

    IPC分类号: A61K31/497 C07D241/36

    CPC分类号: C07D495/04

    摘要: A thienopyrimidine compound of the formula: wherein R1, R2, R3, and R4 are as defined herein, and methods of use of such compounds for the treatment of melanocortin receptor-associated disorders.

    摘要翻译: 下式的噻吩并嘧啶化合物:其中R1,R2,R3和R4如本文所定义,以及使用这些化合物治疗黑皮质素受体相关疾病的方法。

    Linear melanocortin receptor-specific peptides for cachexia
    47.
    发明授权
    Linear melanocortin receptor-specific peptides for cachexia 失效
    线性黑皮质素受体特异性肽用于恶病质

    公开(公告)号:US07754691B1

    公开(公告)日:2010-07-13

    申请号:US11428749

    申请日:2006-07-05

    申请人: Shubh D. Sharma

    发明人: Shubh D. Sharma

    IPC分类号: A61K38/07 A61K38/08

    摘要: Linear peptides with a C-terminus —OH group that are specific for one or more melanocortin receptors, and which may be used in the treatment of melanocortin receptor-mediated disorders, including a variety of body weight disorders including cachexia, and for treatment of inflammation, immune disorders and other conditions, diseases and syndromes, and pharmaceutical compositions including such linear peptides.

    摘要翻译: 具有一个或多个黑皮质素受体特异性的C末端-OH基团的线性肽,其可用于治疗黑皮质素受体介导的病症,包括各种体重紊乱(包括恶病质)和治疗炎症 ,免疫疾病和其他病症,疾病和综合征,以及包括这种线性肽的药物组合物。

    Substituted melanocortin receptor-specific single acyl piperazine compounds
    48.
    发明授权
    Substituted melanocortin receptor-specific single acyl piperazine compounds 有权
    取代的黑皮质素受体特异性单酰哌嗪化合物

    公开(公告)号:US07727991B2

    公开(公告)日:2010-06-01

    申请号:US11464051

    申请日:2006-08-11

    IPC分类号: A61K31/495 C07D295/10

    CPC分类号: C07D241/04 C07D403/12

    摘要: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R2a, R2b, R3a, R3b, r, x and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.

    摘要翻译: 其中J是取代或未取代的单环或双环结构,W是具有至少一个阳离子中心,氢键给体或氢键受体的杂原子单元,Q是通式的黑皮质素受体特异性化合物及其药学上可接受的盐 取代或未取代的芳族碳环基,L,R2a,R2b,R3a,R3b,r,x和y如说明书中所定义,并且带有星号的碳原子可以具有任何立体化学构型。 本文公开的化合物结合一种或多种黑皮质素受体,并且可以是关于一种或多种黑皮质素受体的反向激动剂的激动剂,部分激动剂,拮抗剂,反向激动剂或拮抗剂,并且可以用于治疗一种或多种黑皮质素受体 更多的黑皮质素受体相关病症或障碍,包括特别治疗肥胖症和相关病症。

    Melanocortin receptor-specific piperazine and keto-piperazine compounds
    49.
    发明授权
    Melanocortin receptor-specific piperazine and keto-piperazine compounds 有权
    黑皮质素受体特异性哌嗪和酮 - 哌嗪化合物

    公开(公告)号:US07727990B2

    公开(公告)日:2010-06-01

    申请号:US11464069

    申请日:2006-08-11

    IPC分类号: A61K31/497 C07D295/067

    摘要: Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where X, W, J, Q, L1, L2, L3, R1a, R1b, R2a, and R2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.

    摘要翻译: 通式的黑皮质素受体特异性化合物及其药学上可接受的盐,其中X,W,J,Q,L1,L2,L3,R1a,R1b,R2a和R2b如本说明书中所定义, 星号可以具有任何立体化学构型。 本文公开的化合物结合一种或多种黑皮质素受体,并且可以是关于一种或多种黑皮质素受体的反向激动剂的激动剂,部分激动剂,拮抗剂,反向激动剂或拮抗剂,并且可以用于治疗一种或多种黑皮质素受体 更多的黑皮质素受体相关病症或障碍,包括特别治疗肥胖症和相关病症。

    Small molecule compositions for sexual dysfunction
    50.
    发明授权
    Small molecule compositions for sexual dysfunction 失效
    性功能障碍的小分子组合物

    公开(公告)号:US07550602B1

    公开(公告)日:2009-06-23

    申请号:US11036281

    申请日:2005-01-14

    申请人: Shubh D. Sharma

    发明人: Shubh D. Sharma

    IPC分类号: A01N43/52 C07D235/02

    CPC分类号: C07D487/04

    摘要: Compounds of the general formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and X are as defined. Further provided are methods for treatment of sexual dysfunction, including erectile dysfunction and female sexual dysfunction, and combination drugs and method of use thereof, including a compound of the invention and one or more second sexual dysfunction pharmaceutical agents.

    摘要翻译: 通式化合物或其药学上可接受的盐,其中R 1,R 2,R 3和X如上所定义。 还提供了治疗性功能障碍的方法,包括勃起功能障碍和女性性功能障碍,以及联合药物及其使用方法,包括本发明的化合物和一种或多种第二性功能障碍药剂。